Autoimmune aspects of pulmonary sarcoidosis*

Анна Старшинова; Леонид Чурилов; Геннадий Ершов; Юлия  Зинченко; Петр Яблонский

doi:10.21638/spbu11.2019.419

Авторы

Анна Старшинова ФГБУ "НМИЦ им Алмазова" Минздрава России
Леонид Чурилов St. Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation ;St. Petersburg Research Institute of Phthisiopulmonology, Health Ministry of Russia, 2–4, Ligovskiy pr., St. Petersburg, 191036, Russian Federation
Геннадий Ершов St. Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation
Юлия Зинченко St. Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation ;St. Petersburg Research Institute of Phthisiopulmonology, Health Ministry of Russia, 2–4, Ligovskiy pr., St. Petersburg, 191036, Russian Federation
Петр Яблонский St. Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation ;St. Petersburg Research Institute of Phthisiopulmonology, Health Ministry of Russia, 2–4, Ligovskiy pr., St. Petersburg, 191036, Russian Federation

DOI:

https://doi.org/10.21638/spbu11.2019.419

Аннотация

Despite a plenty of pulmonologic studies, aetiology and pathogenesis of lung sarcoidosis are still insufficiently clear. Most researchers are inclined to speculate about the possible autoimmune/immune-mediated genesis of the disease, finding new evidence of such. The minireview attempted an integral analysis of currently available data suggesting autoimmune origin of sarcoidosis divided into four categories: The role of triggers in the development of sarcoidosis; the presence of immunogenetic susceptibility to the disease; analysis of cellular and humoral immunity in it and evaluation of clinical signs detected in sarcoidosis patients. New original definition of sarcoidosis is suggested. New data are reviewed on the possible autoinflammatory disorder of macrophageal polarization in sarcoidosis distinguishing it from tuberculosis. Author’s original hypothesis on possible therapeutic effectiveness of rapamycin in sarcoidosis is first coined.

Ключевые слова:

sarcoidosis, autoimmunity, triggers, vimentin, major histocompatibility complex, ASIA-syndrome

Скачивания

Данные скачивания пока недоступны.

Библиографические ссылки

References

Cozier Y.C. Assessing the worldwide epidemiology of sarcoidosis: challenges and future directions.Eur. Respir. J., 2016, vol. 48, pр. 1545–1548.

Zinserling V.A., Starinshinova A.A., Karev V.E., Novitskaya Т.А., Mazitova F.M., Belokurov M.,Vasiliev I.V., Pavlova M.V., Zaitsev I.A., Kozak A.R. Features of granulematosis inflammation in Mycoplasma and Chlamidia infection. Zhurnal infectologii. 2015, vol. 7, no. 4, pp. 5–9. (In Russian)

Eishi Y. Etiologic aspect of sarcoidosis as an allergic endogenous infection caused by Propionibacterium acnes. Biomed. Res. Int., 2013, vol. 93, pp. 52–89.

Bindoli S., Dagan A., Torres-Ruiz J.J., Perricone C., Bizjak M., Doria A., Shoenfeld Y. Sarcoidosis and Autoimmunity: From Genetic Background to Environmental Factors. Isr. Med. Assoc. J., 2016, vol. 18,no. 3–4, pp. 197–202.

Ershov G.A., Churilov L.P. On the possible autoimmune nature of sarcoidosis: Which autoantigens involved and why? Clin. Pathophysiol., 2017, vol. 23, no. 3, pp. 77–82. (In Russian)

Watad А., Rosenberg V., Tiosano S. Silicone breast implants and the risk of autoimmune/rheumatic disorders: a real-world analysis. International Journal of Epidemiology, 2018, vol. 47, no. 6, pp. 846–1854.

Perricone C., Shoenfeld Y. Mosaic of Autoimmunity. The Novel Factors of Autoimmune Diseases. Amsterdam, Elsevier, 2019. 728 p.

Georas S.N., Chapman T.J., Crouser E.D. Sarcoidosis and T-helper cells. Th1, Th17, or Th17.1? Amer. J.Respir. Crit. Care Med., 2016, vol. 193, no. 11, pp. 1198–1200.

Musaelyan A., Lapin S., Nazarov V., Tkachenko O., Gilburd B., Mazing A., Mikhailova L., Shoenfeld Y. Vimentin as antigenic target in autoimmunity: a comprehensive review. Autoimmun. Rev., 2018,vol. 17, no. 9, pp. 926–934.

Eberhardt C., Thillai M., Parker R., Siddiqui N., Potiphar L., Goldin R., Timms J.F., Wells A.U., Kon O.M., Wickremasinghe M., Mitchell D., Weeks M.E., Lalvani A. Proteomic analysis of Kveim reagent identifies targets of cellular immunity in sarcoidosis. J. PLoS One, 2017, vol. 12, no. 1, e0170285.

Cain H., Kraus B. Immunofluorescence microscopic demonstration of vimentin filaments in asteroid bodies of sarcoidosis — a comparison with electron microscopic findings. Virchows Arch B. Cell Pathol. Incl. Mol. Pathol., 1983, vol. 42, no 2, pp. 213–226.

Kobak S. Sarcoidosis: a rheumatologist’s perspective. Adv. Musculoskel. Dis., 2015, vol. 7, no. 5,pp. 196–205.

Ahmadzai H., Cameron B., Chui J.J., Lloyd A., Wakefield D., Thomas P. S. Peripheral blood responces to specific antigens and CD28 in sarcoidosis. Respir. Med., 2012, vol. 106, no. 5, pp. 701–709.

Kinloch A.J., Kaiser Y., Wolfgeher D., Ai J., Eklund A., Clark M.R., Grunewald J. In situ humoral immunity to vimentin in HLA-DRB1*03+ patients with pulmonary sarcoidosis. Front. Immunol., 2018, vol. 9, pp. 1516.

Baughman R.P., Lower E.E. Treatment of sarcoidosis. Clin. Rev. Allergol. Immuno., 2015, vol. 49, pp. 79–92.

Crouser E.D., White P., Caceres E.G., Julian M.W., Papp A.C., Locke L.W., Sadee W., Schlesinger L. S. A Novel In Vitro Human Granuloma Model of Sarcoidosis and Latent Tuberculosis Infection. Am. J. Respir. Cell. Mol. Biol., 2017, vol. 57, pp. 487–498.

Ko J.H., Yoon S.O., Lee H.J., Oh J.Y. Rapamycin regulates macrophage activation by inhibiting NLRP3 inflammasome-p38 MAPK-NF?B pathways in autophagy- and p62-dependent manners. Oncotarget, 2017, vol. 8, no. 25, pp. 40817–40831. http://doi.org/10.18632/oncotarget.17256.

Linke M., Pham H.T., Katholnig K., Schnoller T., Miller A., Demel F., Schutz B., Rosner M., Kovacic B., Sukhbaatar N., Niederreiter B., Bluml S., Kuess P., Sexl V., Muller M., Mikula M., Weckwerth W., Haschemi A., Susani M., Hengstschlager M., Gambello M.J., Weichhart T. Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression. Nat. Immunol., 2017, vol. 18, no. 3, pp. 293–302. http://doi.org/10.1038/ni.3655.

Manzia T.M., Bellini M.I., Corona L., Toti L., Fratoni S., Cillis A., Orlando G., Tisone G. Successful treatment of systemic de novo sarcoidosis with cyclosporine discontinuation and provision of rapamune after liver transplantation. Transpl. Int., 2011, vol. 24, pp.